Schering-Plough shipping Gyne-Lotrimin 3 within days of July 29 approval.
This article was originally published in The Tan Sheet
Executive Summary
SCHERING-PLOUGH SHIPPING GYNE-LOTRIMIN 3 TO TRADE following FDA's July 29 approval of the three-day OTC vaginal yeast infection treatment. The company said it plans to begin shipments of the clotrimazole product within days of the approval. Unlike other recently launched three-day treatments, Gyne-Lotrimin 3 is not an Rx-to-OTC switch product since it was never available as an Rx dosage regimen. Schering filed an NDA in September 1994.